6.1 The Committee concluded that the claimed clinical advantages of treating non-melanoma skin cancer using Ambulight PDT were not adequately supported by the limited evidence available, especially in light of the substantial variations in management of small, low-risk lesions. In addition, the pathways of care for using Ambulight PDT in ambulatory care settings are not yet established. The Committee considered that the cost models did not present a robust case for benefits to the NHS.
6.2 The Committee concluded that the case for adoption of Ambulight PDT as a routine treatment for selected patients in place of conventional PDT could not be supported at this stage. Ambulight PDT is one treatment option for people with non-melanoma skin cancer in the community. It is a novel development in the area of PDT that shows some promise, but further work is needed to support its case for adoption in the NHS.